Two Very High Risk Infants with AML with Primary Graft Failure after Cord Blood Transplant Successfully Salvaged with Haploidentical Bone Marrow Graftsdoi:10.1016/s2666-6367(22)00504-8J. AndolinaCarol FriesC. MullenT. FeeneyE. HuseltonJ. Liesveld...
cPoor karyotype vs good and intermediate karyotypes. dIntermediate-2/high risk vs low risk/intermediate-1. eHigher Ang-1 expression vs lower Ang-1 expression. Additionally, patients having higher Ang-1 expression would have higher chance of disease transformation to AML. To the best of our ...
To further investigate the prognostic significance of CPT1A expression, same analyses were executed for the whole cohort of 334 AML (No M3) and National Comprehensive Cancer Network (NCCN) Intermediate-Risk category (n = 173). Compared to CPT1Alow groups, CPT1Ahigh groups still had remarkable ...
Rearrangements of the Mixed Lineage Leukemia (MLL, also known as KMT2A) gene (MLLr) cause aggressive, poor prognosis acute lymphoblastic (ALL) and acute myeloid (AML) leukemias in both children and adults29,30,31 and are associated with very few cooperating mutations32,33,34,35,36. Despite ...
Context Patients with NPM1 AML mutation are included in ELN favorable or intermediate genetic risk categories, although a proportion of these patients will relapse. Thus, it is necessary to identify negative prognostic factors for patientss with NPM1 and to evaluate if ASCT could overcome them. Ob...
Phase I/II Study of the Deacetylase Inhibitor Panobinostat As maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: The Panobest-Trial 8046 Background: Panobinostat (PAN) is an oral pan-histone deacetylase inhibitor (pan-HDACi). Thymus and Activa...
A pilot study of bendamustine in elderly patients with high-risk MDS and AML. 来自 国家科技图书文献中心 喜欢 0 阅读量: 25 作者:C Strupp,S Knipp,J Hartmann,N Gattermann,R Haas,MD U. Germing 摘要: We examined the efficacy of bendamustine in 15 pretreated patients (12 men, 3 women, ...
The presence of measurable residual disease (MRD) at the time of transplant is associated with very high relapse rates, and novel strategies to address relapse risk are needed for these patients. Venetoclax has demonstrated single agent activity in AML, and venetoclax combined with azacitidine, ...
Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were perform
In this phase I trial, 51 newly diagnosed non-favorable risk AML and high-risk MDS patients were enrolled and treated with AcDVP16 (cytarabine 667 mg/m2/day IV continuous infusion days 1–3, daunorubicin 45 mg/m2 IV days 1–3, etoposide 400 mg/m2 IV days 8–10) induction ...